Skip to main content
Log in

Potenzieller Podozytenschaden durch Bardoxolone in klinischen Studien

Genetische oder pharmakologische Aktivierung von Nrf2 erhöht bei chronisch nierenkranken Mäusen die Proteinurie und führt zu Podozytenschaden

Potential podocyte damage from bardoxolone in clinical trials

Genetic or pharmacological activation of Nrf2 increases proteinuria in mice with chronic kidney disease and leads to podocyte damage

  • Für Sie gelesen
  • Published:
Der Nephrologe Aims and scope
  • 1 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Baigent C, Lennon R (2018) Should we increase GFR with bardoxolone in Alport syndrome? J Am Soc Nephrol 29(2):357–359

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Oliver Gross.

Ethics declarations

Interessenkonflikt

O. Gross war von 2018 bis 2020 Hauptprüfer für das einzige deutsche Prüfzentrum der CARDINAL Studie (Sponsor Reata Pharmaceuticals).

Additional information

Redaktion

Thorsten Feldkamp, Hann. Münden

Jens Lutz, Koblenz

Lutz T. Weber, Köln

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, O. Potenzieller Podozytenschaden durch Bardoxolone in klinischen Studien. Nephrologe 17, 57–58 (2022). https://doi.org/10.1007/s11560-021-00548-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-021-00548-5

Navigation